Artelo Biosciences, Inc. ARTL

ARTL Company Overview

Artelo Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of therapeutics that modulate lipid-signaling pathways, particularly the endocannabinoid system. The company operates within the biotechnology and pharmaceutical industries, with research programs targeting cancer supportive care, oncology, anxiety-related disorders, inflammation, and metabolic diseases. Artelo’s core strategy centers on developing proprietary small molecules and biologic compounds designed to address conditions with significant unmet medical need.

The company’s primary pipeline includes ART27.13, a fatty acid binding protein inhibitor being evaluated for cancer-associated anorexia and cachexia; ART26.12, a selective cannabinoid receptor agonist program focused on anxiety and post-traumatic stress-related indications; and ART12.11, a cocrystal cannabidiol formulation platform. Artelo originated from a corporate restructuring and rebranding of Reactive Medical, Inc., later operating as Cellectar Biosciences’ spinout-related entity before adopting its current name in 2018. Its positioning is differentiated by its concentration on cannabinoid science and lipid-signaling therapeutics supported by intellectual property portfolios and specialized drug development expertise.